Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20227072 | 0.81 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL26290153 | 0.79 | LMNA (0.44) | ALDH1A1TDP1KMT2AMAPK1HIF1A | |
| SCHEMBL17860796 | 0.78 | ALDH1A1 (0.41) | ALDH1A1TDP1KMT2AMAPK1HIF1A | |
| SCHEMBL18669821 | 0.75 | ALDH1A1 (0.49) | ALDH1A1TDP1KMT2AMAPK1HIF1A | |
| SCHEMBL16647588 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TDP1KMT2AMAPK1HIF1A | |
| SCHEMBL16644554 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TDP1KMT2AMAPK1HIF1A | |
| SCHEMBL19866627 | 0.73 | ALDH1A1 (0.38) | ALDH1A1TDP1KMT2AMAPK1HIF1A | |
| SCHEMBL18877386 | 0.73 | GAA (0.38) | ALDH1A1TDP1KMT2ALMNAPRKCA | |
| SCHEMBL18877385 | 0.72 | ALDH1A1 (0.40) | ALDH1A1TDP1MAPK1LMNANPC1 | |
| SCHEMBL17863953 | 0.72 | MAPT (0.41) | ALDH1A1TDP1KMT2AMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155384-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155384-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | ALDH1A1 2737/4885TDP1 354/4885KMT2A 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.